Lynparza (olaparib)

Metastatic Castration-Resistant Prostate Cancer and Deleterious or suspected deleterious germline/somatic mutations in the HRR genes BRCA or ATM, monotherapy for the treatment of adult patients with mCRPC who have progressed following prior treatment with a NHA